naltrexone has been researched along with Dyskinesia, Drug-Induced in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ | 1 |
| Bédard, PJ; Grégoire, L; Samadi, P | 1 |
| Adami, H; Avila, M; Hong, LE; Sherr, J; Thaker, GK; Wonodi, I | 1 |
| Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V | 1 |
| Anderson, B; Koz, G; Volavka, J | 1 |
| Ané, M; Blin, O; Fabre, N; Montastruc, JL; Poulik, J; Rascol, A; Rascol, O; Sabatini, U; Senard, JM | 1 |
| Hobart, J; Katzenschlager, R; Lees, AJ; Manson, AJ | 1 |
| McCormick, SE; Stoessl, AJ | 1 |
| Gabel, T; Malcolm, R; Morton, A | 1 |
| Braun, TL; Cadet, JL | 1 |
3 trial(s) available for naltrexone and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Clonazepam; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Naltrexone; Schizophrenia | 2004 |
Naloxone and naltrexone in mental illness and tardive dyskinesia.
Topics: Animals; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Endorphins; Humans; Mood Disorders; Naloxone; Naltrexone; Rats; Schizophrenia | 1982 |
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Topics: Aged; Bromocriptine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Naltrexone; Neurologic Examination; Parkinson Disease | 1994 |
8 other study(ies) available for naltrexone and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu | 2011 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission | 2003 |
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic Agents; AIDS-Related Complex; Amphetamine; Analgesics, Non-Narcotic; Animals; Antiparkinson Agents; Behavior, Animal; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Functional Laterality; Homer Scaffolding Proteins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oxidopamine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
High dose naltrexone for dyskinesias induced by levodopa.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naltrexone; Reproducibility of Results | 2001 |
Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia.
Topics: Animals; Dose-Response Relationship, Drug; Dynorphins; Dyskinesia, Drug-Induced; Fluphenazine; Globus Pallidus; Male; Mastication; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Somatostatin; Substantia Nigra | 2002 |
Idiosyncratic reaction to naltrexone augmented by thioridazine.
Topics: Adult; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Schizophrenia; Sleep Stages; Thioridazine | 1988 |
Naltrexone inhibits the persistent spasmodic dyskinesia induced by chronic intraperitoneal administration of iminodipropionitrile (IDPN).
Topics: Animals; Dyskinesia, Drug-Induced; Mice; Motor Activity; Naltrexone; Nitriles; Time Factors | 1986 |